Take­da an­nounces pos­i­tive new ALK+ lung can­cer da­ta as list of crizo­tinib suc­ces­sors widens

Take­da un­veiled new Phase III front­line da­ta for their ALK in­hibitor at Eu­ro­pean So­ci­ety for Med­ical On­col­o­gy Asia Con­gress, show­ing it could de­ter the spread of lung can­cer for two years or more. But the tri­al com­pared the drug, Alun­brig (briga­tinib), against an ear­ly in­hibitor that is no longer best-in-class and the Japan­ese phar­ma will like­ly face sig­nif­i­cant com­pe­ti­tion if reg­u­la­tors grant an ex­pand­ed la­bel. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER